Postural orthostatic tachycardia syndrome is associated with platelet storage pool deficiency

Gunning, William T. III PhD, FMSA; Karabin, Beverly L. PhD; Blomquist, Thomas M. MD, PhD; Grubb, Blair P. MD

Section Editor(s): Marchi., Rita

doi: 10.1097/MD.0000000000004849
Research Article: Observational Study

Abstract: Mechanisms have been postulated to explain postural orthostatic tachycardia syndrome (POTS), however, the etiology of this often debilitating disorder remains unknown. We conducted a retrospective case–control study of 181 POTS patients who exhibited/reported bleeding symptoms for a specific platelet (PL) dysfunction disorder, delta granule storage pool deficiency (δ-SPD).

Patients were included only if results of blood tests for δ-SPD were available. Electron microscopy was utilized to diagnose δ-SPD. An ELISA assay was used to determine serotonin (5HT) concentration in PLs and medical record review was employed to collect patients’ clinical symptoms.

The most common bleeding symptom was easy bruising (71%) but frequent nose bleeds, heavy menstrual bleeding, and a family history of bleeding were also commonly reported. Of the patients studied, 81% were diagnosed with δ-SPD. Our investigation of 5HT concentration extracted from PLs revealed significantly lower levels of 5HT in POTS patients when compared to that of control subjects. Our data suggest that patients with POTS have significant comorbidities including bleeding symptoms and/or family bleeding histories, and have diminished PL 5HT levels supporting the hypothesis that POTS is a low 5HT level disorder. While we describe a significant relationship with POTS and δ-SPD, this finding does not constitute an etiology for POTS.

Our results establish an additional comorbidity frequently seen in POTS that could explain a number of disparate symptoms often affecting the severity of POTS.

aDepartment of Pathology

bDepartment of Medicine, University of Toledo Medical Center, Toledo, OH.

Correspondence: William T. Gunning III, Department of Pathology, University of Toledo Medical Center, 3000 Arlington Avenue, MS 1090, Toledo, OH 43614 (e-mail:

Abbreviations: δ-SPD = delta granule storage pool deficiency, 5HT = serotonin, BPM = beats per minute, DG = delta granules, HHT = hereditary hemorrhagic telangiectasia (Rendu–Osler–Weber syndrome) disease, PL = platelet, POTS = postural orthostatic tachycardia syndrome, PRP = platelet-rich plasma, SSRI = selective serotonin reuptake inhibitor.

The authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.

The authors have no conflicts of interest to disclose.

This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received July 14, 2016

Received in revised form August 10, 2016

Accepted August 22, 2016

Article Outline
Back to Top | Article Outline

1 Introduction

Postural orthostatic tachycardia syndrome (POTS) is defined clinically as the presence of symptoms of orthostatic intolerance associated with increased heart rate of 30 beats per minute (BPM) from the basal rate or a rate that exceeds 120 BPM that occurs within the first 10 minutes of standing or upright tilt. It is not associated with chronic debilitating conditions such as prolonged bed rest or the use of medications known to diminish vascular or autonomic tone.[1] The syndrome is an abnormal physiological state that is commonly due to an inability of the peripheral vasculature to maintain adequate resistance in the face of orthostatic stress resulting in excessive pooling of blood in the more dependent areas of the body.[2–4] This functional decline in circulatory volume will elicit a compensatory increase in heart rate and myocardial contractility. While compensatory in mild cases, this mechanism is unable to fully compensate in more severe cases, resulting in a reduction in effective circulation and varying degrees of cerebral hypoperfusion. A reduction in arterial blood pressure below the level of cerebral autoregulation due to venous pooling may result in a number of symptoms including dizziness, lightheadedness, near syncope, and ultimately syncope. Episodic syncope, defined as the complete loss consciousness and postural tone with spontaneous recovery, may be quite debilitating in individuals with postural tachycardia. Fortunately, the majority of individuals with postural tachycardia syndrome do not suffer frank syncope; however, the degree of orthostatic intolerance may be so severe as to limit daily function and contribute to a decrease in quality of life. POTS is not a single condition, but rather a heterogeneous group of conditions/disorders that have similar clinical physiological presentations.[5,6] Selective serotonin reuptake inhibitors (SSRIs) are a commonly prescribed treatment for POTS patients.[7,8] SSRIs increase nerve communication and stimulation of the standing vasoconstriction reflex.[9,10] This reduces venous blood pooling and increases orthostatic tolerance which is beneficial in controlling the symptoms in patients with POTS.

The platelet (PL) is the major storage pool of serotonin (5HT) in the circulation containing 99% of all 5HT outside of the central nervous system; the level of circulating 5HT is a key factor for normal cardiovascular function and low levels of 5HT affect vascular tone and subsequently result in cardiac dysfunction.[11] The PL does not synthesize 5HT; it is synthesized by enterochromaffin cells in the gastrointestinal tract and is bound and transported by a specific 5HT transporter (SERT) that leads to packaging of the vasoactive substance in PL dense granules.[12,13] SERT has been reported in many studies to regulate the plasma levels of 5HT and its vasoconstrictive properties are well documented to regulate blood pressure.[12]

Insufficient peripheral 5HT may create conditions that lead to hypotension and excessive bleeding in an individual. Thus, individuals prone to syncope may be deficient in PL dense granules and 5HT. The purpose of this study was to evaluate PL dense (delta) granule storage pool deficiency (δ-SPD) in individuals diagnosed with POTS who also presented with significant bleeding history including symptoms of easy bruising, frequent nose bleeds, and for women, heavy menstrual bleeding. We hypothesized that POTS patients exhibiting clinical symptoms of mucocutaneous bleeding would be PL dense granule deficient. This is the first report of PL storage pool deficiency in a select group of patients having POTS and clinical symptoms suggestive of a PL disorder.

Back to Top | Article Outline

2 Methods

This study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the Institutional Review Board of The University of Toledo Medical Center. A total of 181 patients were the subjects of this retrospective case–control evaluation. Patients included in this study had been diagnosed with POTS in our cardiology clinic via history, physical, and tilt-table test in the fasting state and also had a history of prominent bleeding symptoms for which blood had been analyzed for δ-SPD during a 10-year period (2006–2015). All had a 6 months or greater history of orthostatic intolerance manifested by orthostatic tachycardia with a heart rate increase of at least 30 BPM (or a rate exceeding 120 BPM) observed during the first 10 minutes of upright posture without orthostatic hypotension, weakness, light-headedness, fatigue, and near syncope.[3,5] Although many of our patients reported frequent epistaxis, we did not consider a comorbidity of hereditary hemorrhagic telangiectasis (HHT) disease (Rendu–Osler–Weber syndrome), as notation of telangiectasis, arteriovenous malformations, nor a family history of HHT was included in their medical records.[14]

Tilt-table testing utilized a 70° baseline upright tilt for 30 minutes, during which time heart rate and blood pressure were monitored continually.[5] The test was ended if symptomatic hypotension and bradycardia occurred, reproducing the patient's symptoms. If the patient did not experience symptoms, an intravenous infusion of isoproterenol was initiated in the supine position with a dose sufficient to raise the heart rate to 20% to 25% above the resting value. Subsequently, up-right tilt was repeated for 15 minutes. Patients who were on chronic antihypertensive, diuretic, anticholinergic, or antidepressant medications, those with diabetic neuropathy or multisystem disease of any etiology were excluded. Each patient had undergone a thorough history and physical examination as well as detailed blood chemistry analysis and thyroid profile analysis. Patients were also excluded if taking an SSRI for therapeutic management of their condition. POTS patients without a history or symptoms of bleeding were not included in the study.

Our retrospective study employed female subjects recruited to establish normal controls. Control subjects (41) were vetted using a bleeding questionnaire, aggregation assay, PL 5HT levels, and PL delta granule (DG) content determination. They were volunteers without any history of syncope episodes, without history of common bleeding symptoms and had normal numbers of PL DGs (4–6 DG/PL) and normal 5HT concentrations (200–800 ng/109 PLs) extracted from PLs.

Platelet-rich plasma (PRP) was obtained from whole blood by centrifugation at room temperature for 15 minutes at 200g. Electron microscopy coated copper grids used for PL support were washed with deionized water following PRP incubation and air-dried. A FEI Tecnai G2 Spirit BioTwin transmission electron microscope (Hillsboro, OR) was used determine an average number of DG/PL. Previous studies from this laboratory have established a normal of 4.60 + 0.47; mean ± 1 standard deviation (SD) DG/PL, consistent with the established literature. PL 5HT concentration was determined by ELISA using commercially available kits and expressed in nanograms × 109 PLs.[15]

Unless otherwise stated, data are presented as mean + 1 SD. Chi-square and Fisher exact test were performed using the SAS System (SAS Institute, Inc., Cary, NC) and graphed using SigmaPlot (SSPS, Inc., Chicago, IL).

Back to Top | Article Outline

3 Results

3.1 Demographics

All patients included in the study were diagnosed with POTS by tilt-table analysis and all had symptoms of a bleeding diathesis including histories of frequent epistaxis, easy bruising, and/or heavy menstrual bleeding. Patient demographics are listed in Table 1. This table lists the percentage of a variety of clinical symptoms observed; some symptoms were not noted in all patient medical records, therefore, some of the calculated percentages were based upon fewer observations. Disorders associated with low 5HT levels are illustrated in Fig. 1. While we cannot be certain that these symptoms are absolutely related to diminished 5HT stores in the PLs, the constellation of clinical presentations we observed demonstrates a significant heterogeneity of symptoms suggested to be due to low 5HT as described in the literature.[9,16,17]

Back to Top | Article Outline

3.2 Joint mobility

The incidence of excessive joint mobility was significant for 69.3% of the patients included in this study with 21.6% of these having a Beighton score of 6 or greater (a score 4 or more of 8 joints plus the trunk affected (>4/9) is consistent with a diagnosis of joint hypermobility) by physical examination (P < 0.001). Other symptoms affecting joints and the vasculature included 31.7% (57/180, P < 0.001) experiencing Raynaud phenomenon and 17.7% (32/181, P < 0.001) complained of arthralgia.

Back to Top | Article Outline

3.3 Bleeding symptoms

Bleeding symptoms included easy bruising (71.3%; 129/181, P < 0.001), epistaxis (33.1%; 59/178, P < 0.001), heavy menstrual bleeding (32.1%; 54/168, P < 0.001), anemia (22.7%; 41/181, P < 0.001), endometriosis (6.7%; 11/163, P = 0.11), or a significant postsurgical bleeding event (3.2%; 5/156, P = 0.28). Patients had fewer red cells than normal as well as low hemoglobin and hematocrit consistent (all, P > 0.001) with the frequency of anemia described earlier (Table 2). All other cell counts were within normal limits.

Back to Top | Article Outline

3.4 Platelet dense granules

Our patients’ average number of DG/PL was 2.91 ± 1.23 compared with our control group (4.40 ± 0.55 DG/PL, P < 0.001; Figs. 2 and 3). Eighty-one percent (146/181, P < 0.001) had a deficiency of PL dense granules.

Back to Top | Article Outline

3.5 Serotonin

Determination of PL 5HT concentration was added during the latter years of our study, once frequent clinical symptoms associated with low 5HT levels was recognized. 5HT extracted from PLs obtained from PRP and normalized to 109 PL/mL was analyzed by ELISA for 65 of our patients. The mean 5HT concentration was 271.05 ± 35.19 ng/109 PLs (±SE, P < 0.001; normal range 200–800 ng/109 PLs). Our control group 5HT concentration was 664.15 ± 38.6 ng/109 PLs (Fig. 3).

Back to Top | Article Outline

3.6 Other common symptoms

A variety of additional symptoms for these patients was also noted in their medical history (Table 1). Most frequently reported was cognitive issues (37.5%; 66/176, P < 0.001), depression (33.1%; 60/181, P < 0.001), anxiety (29.8%; 54/181), and sleep disorders (20%; 36/180, P < 0.001); attention deficit disorders were noted for 7.1% (9/127) of the patients.

Back to Top | Article Outline

4 Discussion

The aim of this retrospective study was to investigate a potential relationship between POTS and PL dysfunction. The study was restricted to POTS patients with anemia, and/or had clinical symptoms of bleeding, and had been evaluated by electron microscopy. The most common bleeding symptom was easy bruising (71.3%, P < 0.001), but frequent nose bleeds, heavy menstrual bleeding and a family history of bleeding were also frequently reported. Most of these patients had excessive joint mobility and complained of fatigue; 81% (P < 0.001) were diagnosed with a PL δ-SPD. Significantly lower levels of 5HT were found in POTS patients when compared to control subjects. Our data demonstrate POTS patients with bleeding symptoms have diminished PL 5HT stores supporting the hypothesis that POTS is a low 5HT disorder.[9]

POTS has been described as the most common form of orthostatic intolerance, affecting approximately 500,000 people in the United States.[18] The diagnosis of POTS can be readily made by tilt-table assessment finding a pulse greater than 120 beats/minute or an elevation of pulse of 30 BPM in the first 10 minutes of elevation into an upright position, which is different than the fall of blood pressure as seen in vasovagal syncope under the same conditions. It is the least severe of the dysautonomias, however, dysfunction of the autonomic nervous system in POTS tends to be more severe with numerous associated symptoms than observed in typical cases of neurocardiogenic syncope.[19,20]

The disorder is often misdiagnosed as chronic anxiety or a panic disorder because the autonomic failure in these patients is not severe and the variety of clinical symptoms including fatigue, lightheadedness, nausea, headache, near syncope, and exercise intolerance is subtle.[19,20] Furthermore, POTS may be idiopathic and unrelated to other diseases, with most affected patients categorized with a partial dysautonomic condition appearing to be related to mild peripheral autonomic neuropathy.[19,20]

The female/male ratio of 17:1 in our study is significantly greater than usually described at 5:1; a recent epidemiology study of 3002 patients reported a female to male ration of 3:1 with a median age of 23, a significantly younger age than other forms of syncope.[21] The increased frequency of affected females in our study might be related to the specific comorbidity of bleeding diathesis; patients without bleeding symptoms had not been evaluated for δ-SPD, a limitation of our study. With the heterogeneity of symptoms associated with POTS, a variety of proposed etiologies have been suggested yet no conclusive basis nor mechanism have been established.[22–26]

We report a significant relationship with PL δ-SPD that may explain many of the symptoms reported with POTS. Patients previously diagnosed with POTS by tilt-table assessment with additional prevalent bleeding symptoms were also evaluated for δ-SPD by electron microscopy. For the entire group of 181 POTS patients, the mean of 2.91 ± 1.23 DG/PL is significantly different than control subjects (4.40 ± 0.55 DG/PL (P < 0.001)); 81% (147/181) were diagnosed with δ-SPD. PL dysfunction disorders usually manifest with common symptoms including easy bruising, frequent nose bleeds, heavy menstrual bleeding for women, excessive bleeding of the gums with brushing, and excessive bleeding with surgery or trauma. The condition is thought to have a dominant inheritance pattern but is also known to be acquired. Interestingly, 1 drug that has been shown to reduce bleeding symptoms related to δ-SPD (desmopressin) has also been reported to reduce symptoms in POTS.[27]

As stated previously, only patients diagnosed with POTS with a bleeding history, symptoms of bleeding, and/or anemia were included in this study. PL 5HT concentration was not determined during many of the early years when patients were initially evaluated for PL dysfunction, however our 5HT data are sufficient (n = 65) to conclude PL 5HT concentration was significantly decreased in patients with POTS compared with control subjects (P < 0.001).

The diminished concentration of 5HT in our patients appears to trend with decreased numbers of PL dense granules; 5HT is stored in these organelles. The variety of complaints such as fatigue, migraine headache, nausea, and irritable bowel syndrome/disease has been reported due to low 5HT. We found no statistical evidence of correlation via a number of analyses for symptom associations. Patients without bleeding symptoms but having symptoms related to low 5HT would suggest a causal, rather than correlative, relationship with PL dysfunction. Conversely, PL dysfunction and bleeding could be unrelated to POTS.

The PL dense granules contain ADP, ATP, 5HT, calcium, and pyrophosphates at different concentrations (e.g., there is 9–10 times as much ADP than ATP in dense granules with the converse of adenine nucleotide concentrations in the PL cytosol). The transporters for PL uptake of dense granule constituents are different for each of these substances; it is not unreasonable to assume that there could be a PL storage pool deficiency for any of these substances independent of PL number and function. A defect of SERT might lead to low levels of 5HT within PL dense granules but would not affect dense granule number nor ADP concentration. Studies have defined δ-SPD as a condition of increased PL ATP/ADP ratios exceeding 2.0 directly related to diminished granular ADP stores and that decreased ADP levels correlate with reduced numbers of PL dense granules.[28–30] We and others have found that δ-SPD and diminished PL 5HT stores also correlate with one another.[31,32] Although we have identified a significant deficiency of the PL dense granules in these patients, not all of the patients were diagnosed with δ-SPD; 19% were found to be within normal limits.

Back to Top | Article Outline

5 Conclusions

We report an association of PL δ-SPD, with low PL concentrations of 5HT in POTS patients who also exhibited symptoms of a potential bleeding diathesis. A number of comorbidities in these patients may be explained by having low 5HT levels in the circulation. These results suggest a potential role of diminished synthesis of 5HT or a potential PL dysfunction to consider for study for the etiology of POTS. Future studies planned include a case–control study that will utilize a formal bleeding checklist as used for the establishment of our control group, assessment of menstrual bleeding using a vetted scoring rubric, and inclusion of all primary POTS patients with and without bleeding symptoms to further evaluate our postulates.

Back to Top | Article Outline


We are indebted to Dr Sadik Khuder, Professor of Medicine at the University of Toledo and an expert statistician for review of our data.

Back to Top | Article Outline


1. Grubb BP, Karabin B. Cardiology patient pages. Postural tachycardia syndrome: perspectives for patients. Circulation 2008; 118:e61–e62.
2. Gazit Y, Nahir AM, Grahame R, et al. Dysautonomia in the joint hypermobility syndrome. Am J Med 2003; 115:33–40.
3. Grubb BP, Kanjwal Y, Kosinski DJ. The postural tachycardia syndrome: a concise guide to diagnosis and management. J Cardiovasc Electrophysiol 2006; 17:108–112.
4. Rowe PC, Barron DF, Calkins H, et al. Orthostatic intolerance and chronic fatigue syndrome associated with Ehlers-Danlos syndrome. J Pediatr 1999; 135:494–499.
5. Low PA, Sandroni P, Joyner M, et al. Postural tachycardia syndrome (POTS). J Cardiovasc Electrophysiol 2009; 20:352–358.
6. Benarroch EE. Postural tachycardia syndrome: a heterogeneous and multifactorial disorder. Mayo Clin Proc 2012; 87:1214–1225.
7. Kanjwal K, Karabin B, Kanjwal Y, et al. Outcomes of pregnancy in patients with preexisting postural tachycardia syndrome. Pacing Clin Electrophysiol 2009; 32:1000–1003.
8. Mar PL, Raj V, Black BK, et al. Acute hemodynamic effects of a selective serotonin reuptake inhibitor in postural tachycardia syndrome: a randomized, crossover trial. J Psychopharmacol 2014; 28:155–161.
9. Grubb BP, Karas BJ. The potential role of serotonin in the pathogenesis of neurocardiogenic syncope and related autonomic disturbances. J Interv Card Electrophysiol 1998; 2:325–332.
10. Schroeder C, Tank J, Boschmann M, et al. Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance. Circulation 2002; 105:347–353.
11. Cote F, Fligny C, Fromes Y, et al. Recent advances in understanding serotonin regulation of cardiovascular function. Trends Mol Med 2004; 10:232–238.
12. Brenner B, Harney JT, Ahmed BA, et al. Plasma serotonin levels and the platelet serotonin transporter. J Neurochem 2007; 102:206–215.
13. Weiss HJ, Tschopp TB, Rogers J, et al. Studies of platelet 5-hydroxytryptamine (serotonin) in storage pool disease and albinism. J Clin Invest 1974; 54:421–433.
14. Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000; 91:66–67.
15. Fouassier M, Bourgerette E, Libert F, et al. Determination of serotonin release from platelets by HPLC and ELISA in the diagnosis of heparin-induced thrombocytopenia: comparison with reference method by [C]-serotonin release assay. J Thromb Haemost 2006; 4:1136–1139.
16. Davis JM, Alderson NL, Welsh RS. Serotonin and central nervous system fatigue: nutritional considerations. Am J Clin Nutr 2000; 72:573S–578S.
17. Mitro P, Hijova E, Mudrakova K. Role of the peripheral serotoninergic system in the pathogenesis of vasovagal syncope. Bratisl Lek Listy 2006; 107:248–252.
18. Robertson D. The epidemic of orthostatic tachycardia and orthostatic intolerance. Am J Med Sci 1999; 317:75–77.
19. Boris JR. The role of the cardiologist in the evaluation of dysautonomia. Cardiol Young 2010; 20 (Suppl 3):135–139.
20. Kanjwal Y, Kosinski D, Grubb BP. The postural orthostatic tachycardia syndrome: definitions, diagnosis, and management. Pacing Clin Electrophysiol 2003; 26:1747–1757.
21. Cooke J, Carew S, Costelloe A, et al. The changing face of orthostatic and neurocardiogenic syncope with age. QJM 2011; 104:689–695.
22. Agarwal AK, Garg R, Ritch A, et al. Postural orthostatic tachycardia syndrome. Postgrad Med J 2007; 83:478–480.
23. Furlan R, Jacob G, Snell M, et al. Chronic orthostatic intolerance: a disorder with discordant cardiac and vascular sympathetic control. Circulation 1998; 98:2154–2159.
24. Grubb B, Dan GA. Syncope due to autonomic insufficiency syndromes associated with orthostatic intolerance. Rom J Intern Med 2000; 38–39:3–19.
25. Medow MS, Stewart JM. The postural tachycardia syndrome. Cardiol Rev 2007; 15:67–75.
26. Raj SR. Postural tachycardia syndrome (POTS). Circulation 2013; 127:2336–2342.
27. Coffin ST, Black BK, Biaggioni I, et al. Desmopressin acutely decreases tachycardia and improves symptoms in the postural tachycardia syndrome. Heart Rhythm 2012; 9:1484–1490.
28. Holmsen H, Storm E, Day HJ. Determination of ATP and ADP in blood platelets: a modification of the firefly luciferase assay for plasma. Anal Biochem 1972; 46:489–501.
29. Gerrard JM, Rao GH, White JG. The influence of reserpine and ethylenediaminetetraacetic acid (EDTA) on serotonin storage organelles of blood platelets. Am J Pathol 1977; 87:633–646.
30. Girotti S, Ferri E, Cascione ML, et al. Methodological problems of direct bioluminescent ATP assay in platelets and erythrocytes. J Biolumin Chemilumin 1989; 4:594–601.
31. Engelmann G, Morgenstern E, Wolf N, et al. Delta-storage pool disease in infancy with absence of blood serotonin associated with psychomotor retardation. Pediatr Hematol Oncol 2001; 18:355–357.
32. Rinker L, Zadzilka N, Kanjwal M, et al. Platelet delta granule and serotonin concentrations are decreased in patients with postural orthostatic tachycardia syndrome. Blood 2009; 114:995.

platelets; POTS; serotonin; storage pool deficiency; tachycardia

Copyright © 2016 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.